Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2025

Revenue declinedProfit growth above 25%Auditor changed mid-yearResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.6%Reaction day

₹35.82

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%+6.1% vs market

Non Banking Financial Company (NBFC) peers, median of 199sector-0.4%+5.0% vs sector

On the reaction day the stock moved 6.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Non Banking Financial Company (NBFC) peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.6-1.5+6.1-0.4+5.0

Next day

+0.9-2.2+3.1-0.7+1.6

+9.7-1.2+10.9-0.6+10.3

+13.2-0.9+14.1-0.9+14.1

+7.9-2.3+10.2-1.6+9.5

+8.9-2.5+11.4-1.4+10.3

+4.7-3.6+8.3-2.7+7.4

15d

+2.3-10.4+12.7-7.5+9.8

+11.1-11.3+22.4-9.0+20.0

+34.8-3.6+38.3-6.4+41.2

+14.5+3.9+10.6-2.9+17.3

UpDownMarket · Nifty Microcap 250Sector · Non Banking Financial Company (NBFC) peers, median of 199Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Titan Securities' board approved standalone and consolidated unaudited results for Q3 FY26 (ended Dec 31, 2025) on Feb 12, 2026. On a standalone basis, total income fell sharply to Rs. 101.25 lakhs from Rs. 334.90 lakhs in the same quarter last year, a drop of nearly 70%. Standalone profit after tax also declined to Rs. 37.88 lakhs (vs Rs. 71.37 lakhs in Q3 FY25), with EPS falling to Rs. 0.15 from Rs. 0.29. However, on a consolidated basis, PAT jumped to Rs. 367.18 lakhs in Q3 FY26 from Rs. 254.34 lakhs a year ago (about 44% growth), driven mainly by Rs. 329.30 lakhs share of profit from associates Titan Biotech and Peptech Biosciences. Consolidated EPS rose to Rs. 1.47 from Rs. 1.02. The new statutory auditor, Goyal Nagpal & Co, issued unmodified review reports, and noted that prior period results were reviewed by the predecessor audit firm, indicating a recent auditor change.

Likely market impact

Standalone performance is weak with a steep revenue and profit decline, but consolidated numbers look healthier thanks to associate company contributions, which cushion overall profitability. Shareholders should note the auditor change and the heavy dependence on associate earnings for consolidated growth.